Medscape: Analysis boosts Fluvoxamine for COVID, but what's the evidence?
UC expert says research may be useful, but more trials are needed
A report published recently in JAMA Open Network finds there's a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients. However, outside experts cited by Medscape differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 treatment arsenal. One of those experts sources is Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.
Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine/Photo/Joe Fuqua II/UC Creative + Brand
"This research might be valuable, but the jury remains out until several other adequately powered and designed trials are completed," said Fichtenbaum, who's familiar with the findings. "I'm not sure how useful this is given we have several antiviral agents available. Why would we choose this over Paxlovid, remdesivir, or molnupiravir?"
According to Fichtenbaum, researchers began focusing on fluvoxamine after case reports about patients improving while on the medication. This led to further interest, he said, boosted by the drug's known ability to dampen the immune system.
Lead photo/Science News
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's medical, graduate and undergraduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Texas stabbing led to online hate and misinformation
May 21, 2026
UC Professor Jeffrey Blevins talks to the Dallas Morning News about how outside agitators seize on tragedy to push their agendas.
6 ways starting a GLP-1 medication could affect your emotions
May 20, 2026
When patients first start taking a glucagon-like peptide-1 (GLP-1) medication, they probably expect to feel full. But they might not anticipate how it can influence their emotions. The medications act on the stomach and the brain, said Malti Vij, MD, a University of Cincinnati adjunct associate professor in the College of Medicine's Department of Internal Medicine and a diplomate of the American Board of Obesity Medicine.
UC researchers recruit older adults for extreme heat health study
May 20, 2026
The University of Cincinnati’s Center for Collaboration on Climate & Community for Health (C4H) is recruiting older adults to participate in a study tracking their health during periods of extreme summer heat.